1.35 m babies are born with a congenital heart defect each year. Of these, 400,000 have heart valve defects, but there is no durable valve replacement on the market! We are fulfilling that unmet clinical need with a completely new prosthetic valve for adults and children, implanted using a low-risk transcatheter technique. Our valve is made from patient-donated (endogenous) tissue, giving it lifelong durability: a once-in-a-lifetime solution that is affordable for patients and healthcare providers worldwide.Learn more
GrOwnValve is a pre-clinical stage medical device company, developing a unique heart valve prosthesis system. The first product, the AdultValve and the second product, the ChildValve including a bioresorbable anchoring device will come to market as a procedure pack that enables a safe, affordable and easy-to-use minimally invasive heart valve replacement made from the patient’s own tissue.
Our main goal is to offer a lifelong cure to patients with heart valve defects worldwide. Our innovation eliminates the need for repeated heart valve replacement surgery and lifelong medication.
Engineer 3D Technology
QM Production and Process Quality
Regulatory and Business Development
Research and Development Engineer
We are glad to announce that we got funded by the DZHK for conducting our first clinical trial in adult patients starting in 2022.
We are very happy to be nominated #ScienceBreakthrough of the year by the Falling Walls Foundation award!
In 2019 Spark helped kick-start the bioresorbable stent solution to make the GrOwnValve innovation a possible treatment for small (growing) patients.
In july 2018 the GrOwnValve Project Team won the BPW Canvas business plan price by the IBB Berlin.
We are very proud to have been able to be part of the research consortium that was able to reach a Sciencemag publication.
In Autumn of 2017 the GrOwnValve Project was rewarded the EXIST translational grant to bring the innovative technology into preclinical testing.
Our co-founder Jasper Emeis was interviewed about the win of the EIC by the Healthcapital online-magazin.
GrOwnValve wins the INAM Innovation Challenge 2021.
From August 2021 the EXIST II funding programme supported GrOwnValve for one year to establish Quality and Risk Management.
By November 2021 the Project "Kleine Patienten - Großer Bedarf" administered by VDI was granted by the federal ministry of education and research.
From April 2022 on the EIC Accelerator will help our first products to bridge the gap to clinical application.
We are glad to be able to announce that our first clinical trial in (young) adult patients starting in 2023 will be funded by the DZHK.
ZDF released a documentary about cardiac health featuring GrOwnValve as an example of cutting edge RnD from minute 37 on.